id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-N-3226-0003,FDA,FDA-2022-N-3226,Request for Extension from Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO),Other,Request for Extension,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T20:00:22Z,,0,0,090000648555b380
FDA-2022-N-3226-0001,FDA,FDA-2022-N-3226,Opportunity for Feedback on Development and Dissemination of Educational Materials on Rare Disease Drug Development,Other,Public Participation,2022-12-16T05:00:00Z,2022,12,2022-12-16T05:00:00Z,2023-05-01T03:59:59Z,2026-01-03T12:25:16Z,,1,0,090000648553affa